Shares of Adamas Pharmaceuticals (NASDAQ:ADMS) rose in after-market trading after the company reported Q4 results.
Quarterly Results
Earnings per share rose 22.89% over the past year to ($0.64), which missed the estimate of ($0.51).
Revenue of $21,010,000 rose by 28.52% from the same period last year, which beat the estimate ...
Full story available on Benzinga.com